
WilmerHale Advises Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medicine in Establishment of Bridge Medicines

NOVEMBER 11, 2016

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

Bridge Medicines builds upon the work of the independent, nonprofit Tri-Institutional Therapeutics Discovery Institute, known as Tri-I TDI. Scientists at the Tri-I TDI, which launched in 2013, are working in the laboratory on approximately 50 early-stage drug discovery projects spanning therapeutic areas including infectious disease, oncology, neuropsychiatry and rare diseases with the hope that they might be translated into future treatments for patients.

WilmerHale advised Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medicine in this transaction. The team was led by Transactional Department Chair [Steve Singer](#) and included Partner [Rob Burke](#) and Counsel [Kaylan Sliney](#).

[Read the complete press release.](#)